Last reviewed · How we verify
NCT05813171: TEA-PARTY
The Effects of Allicor on Patients After Revascularization Treatment During a Year
Phase 4 trial testing Allicor in Atherosclerosis in 300 participants. Status unknown.
20 April 2024
Quick facts
| Lead sponsor | Institute for Atherosclerosis Research, Russia |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 300 |
| Start date | 20 April 2023 |
| Primary completion | 20 April 2024 |
| Estimated completion | 31 May 2024 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Allicor
- Placebo
Conditions studied
- Atherosclerosis — all drugs for Atherosclerosis →
- Peripheral Arterial Disease — all drugs for Peripheral Arterial Disease →
Sponsor
Institute for Atherosclerosis Research, Russia
Who can join
Adults 40 to 75, any sex, with Atherosclerosis or Peripheral Arterial Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A significant challenge in medical care is atherosclerotic occlusion of peripheral arteries, such as lower extremities and brachiocephalic arteries, which can eventually lead to loss of limbs or fatal ischemic strokes. Revascularizing surgical interventions can restore the lumen of the arteries and provide an effective way to treat such patients. However, up to a third of patients need re-intervention or experience cardiovascular complications within a year after surgery. The purpose of this study is to evaluate the effect of adding the natural dietary supplement Allicor to conventional treatment on the incidence of cardiovascular complications and treatment effectiveness 12 months after revascularization. Another valuable area of investigation is the search for predictors of long-term cardiovascular complications after revascularization, which could be markers of inflammation and heteroplasmy levels in the patient's mitochondrial genome.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Role of PTEN-Induced Protein Kinase 1 as a Mitochondrial Dysfunction Regulator in Cardiovascular Disease Pathogenesis.
Gwon JG, Lee SM. · · 2024 · cited 9× · PMID 38486493 · DOI 10.5758/vsi.230116
Verify or expand the search:
- PubMed search for NCT05813171
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Allicor
Trials testing the same drug.
- NCT05803759 — The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment · Phase 4 · unknown
Other recruiting trials for Atherosclerosis
Currently open trials in the same condition.
- NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT06788431 — A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary · EARLY_PHASE1 · recruiting
- NCT06676046 — Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions · recruiting
- NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting
Other Institute for Atherosclerosis Research, Russia trials
Trials by the same sponsor.
- NCT06590012 — Evaluating the Impact of 'Tertinat' on Patients with Atherosclerosis-Related Cardiovascular Diseases · Phase 2 · recruiting
- NCT05803759 — The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment · Phase 4 · unknown
- NCT03877523 — Cocarnit Effects on Macrophages Polarization · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05813171 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute for Atherosclerosis Research, Russia
- Last refreshed: 19 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05813171.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing